Investigational New Drug Application Submissions for Individualized An
fda.gov
news
2022-10-21 11:19:00

In this section: Search for FDA Guidance Documents 
 Docket Number: FDA-2021-D-1139 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research 
 The purpose of this guidance is to provide recommendations regarding the chemistry, manufacturing, and controls (CMC) information that should be provided in an investigational new drug application (IND) submitted by a sponsor-investigator (hereafter referred to as sponsor) developing an individualized antisense oligonucleotide (ASO) drug product for a severely debilitating or life-threatening (SDLT) disease caused by a unique genetic variant where only a small number of individuals are prospectively identified (typically one or two).
